SAN FRANCISCO, May 15 /PRNewswire/ -- Mallinckrodt Inc. (NYSE: MKG) today
announced that the company has received FDA approval to market its
OxiFirst(TM) fetal oxygen monitoring system in the United States. The OxiFirst
system is the world's first solution for continuous, direct monitoring of
fetal oxygen status during labor and delivery.
The company will officially launch the system at a press conference
scheduled for 10:30 AM (PST) on May 18, 2000 at the Ritz Carlton Hotel in San
Francisco. The press conference will feature three of the leading
obstetricians in the United States who participated in the randomized, multi-
center clinical trial of fetal oxygen monitoring technology, as well as one of
the developers of the technology.
The press conference proceedings will be broadcast live on the Internet
through OBGYN.NET (http://www.obgyn.net) and iVillage.com: The Women's Network on the
pregnancy page of the allHealth channel (http://www.allhealth.com/womens/pregnancy).
For more information on the OxiFirst system and the press conference,
journalists may contact Tony Labriola or Kara Nadeau at Mullen Public
Relations, 978-468-1155 or Barbara Abbett at Mallinckrodt, 314-654-5230.
About Mallinckrodt
Mallinckrodt Inc. is a global manufacturer and marketer of specialty
medical products designed to sustain breathing, diagnose disease and relieve
pain. Named one of America's most admired medical products and equipment
companies by Fortune magazine, Mallinckrodt does business in more than 100
countries. In fiscal 1999, combined net sales were $2.6 billion for
Mallinckrodt's respiratory, imaging and pharmaceutical product lines. Based in
St. Louis, Missouri, Mallinckrodt's web site address is: http://www.mallinckrodt.com.
SOURCE Mallinckrodt Inc.
 back to top
Related links:
http://www.mallinckrodt.com
CONTACT:
Tony Labriola, tlabriola@mullen.com or Kara
Nadeau, knadeau@mullen.com of Mullen PR, 978-468-1155 or Barbara
Abbett of Mallinckrodt Inc., 314-654-5230, barbara.abbett@mkg.com
|
